Showing 461-470 of 2123 results for "".
- Second Opinionshttps://practicalneurology.com/columns/practice-management/second-opinions/31358/The November 2005 issue of *Practical Neurology* features pivotal discussions tailored for healthcare professionals in the field of neurology. A standout article, “Joining Forces: Are Professional Associations Worth Your While?”, delves into the advantages of affiliating with professional organizati
Bionic Breakout: Robotic-Assisted Therapy Is Evolving
https://practicalneurology.com/columns/practice-management/bionic-breakout-robotic-assisted-therapy-is-evolving/30726/Robotic-assisted therapy has made significant strides in the past 15 years. Will it overtake conventional physical therapy?Practice Management Deadlines Loom for Clinical Neurologists
https://practicalneurology.com/columns/practice-management/practice-management-deadlines-loom-for-clinical-neurologists/30811/Learn what you need to do to comply with new initiatives and protect your practice from fines and penalties.- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31129/Pharmacological Management of Myasthenia Gravis in Young Adults Versus Older PatientsManaging myasthenia gravis (MG) requires tailored pharmacological strategies, especially when comparing young adults to older individuals with similar disease severity. Experts Dr. Henry J. Kaminski and Dr. Zohar Ar
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31171/Thrombolytic therapy for acute ischemic stroke, specifically tissue plasminogen activator (tPA), remains significantly underutilized, with treatment rates persisting below five percent despite robust evidence supporting its efficacy and safety. Since the FDA approved tPA for stroke in 1996, multiple
- From Exam Room to Board Roomhttps://practicalneurology.com/columns/practice-management/from-exam-room-to-board-room/31418/Pharmaceutical Consulting Opportunities for NeurologistsIn recent years, many private neurologists have increasingly collaborated with pharmaceutical companies, driven by factors such as frustration with third-party payers, advancements in clinical innovations, and the blurred lines between clinical
Mastering Migraine
https://practicalneurology.com/programs/practical-neurology/mastering-migraine/35575/Melody Barthelemy, a human resources specialist, details her experiences living with migraine, including strategies for tracking episodes and thriving with a busy career. She is joined by Dawn C. Buse, PhD, Clinical Professor, Albert Einstein College of Medicine, New York, NY, who discusses recent rMigraine in Children
https://practicalneurology.com/diseases-diagnoses/child-neurology/migraine-in-children/31514/Headache is common in children and adolescents and there are exciting developments in diagnosis, classification, and treatment.Update on Noninvasive Neuromodulation Devices for Headache Treatment
https://practicalneurology.com/diseases-diagnoses/headache-pain/update-on-noninvasive-neuromodulation-devices-for-headache-treatment/32129/Neuromodulation devices are effective in primary headache management, present low risk, and have minimal to no adverse events but require an understanding of how they can be integrated into the therapeutic armamentarium.Post-traumatic Pan-Syringomyelia, Case Report and Review of Literature
https://practicalneurology.com/diseases-diagnoses/headache-pain/post-traumatic-pan-syringomyelia-case-report-and-review-of-literature/30575/Post-traumatic syringomyelia, a complication associated with severe pain and sensory and motor findings, may start months or years after a spinal cord injury.